- Home
- QUBT vs TSHA Comparison
QUBT vs TSHA Comparison
Compare QUBT & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QUBT | TSHA |
|---|---|---|
| Founded | 2001 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | QUBT | TSHA |
|---|---|---|
| Price | $8.47 | $4.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $18.00 | $10.56 |
| AVG Volume (30 Days) | ★ 10.4M | 2.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 62.50 |
| EPS | ★ N/A | N/A |
| Revenue | $373,000.00 | ★ $8,333,000.00 |
| Revenue This Year | $124.37 | N/A |
| Revenue Next Year | $318.32 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 4.18 | N/A |
| 52 Week Low | $4.37 | $1.13 |
| 52 Week High | $25.84 | $6.02 |
Technical Indicators
Market Signals| Indicator | QUBT | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 44.40 | 43.61 |
| Support Level | $7.70 | $4.41 |
| Resistance Level | $12.98 | $5.39 |
| Average True Range (ATR) | 0.59 | 0.24 |
| MACD | 0.13 | 0.00 |
| Stochastic Oscillator | 44.39 | 19.86 |
Price Performance
Historical ComparisonAbout QUBT Quantum Computing Inc.
Quantum Computing Inc is an integrated photonics and quantum optics technology company that provides accessible and affordable quantum machines to the world today. Its products are designed to operate at room temperature and low power at an affordable cost. The Company's portfolio of core technologies and products offer capabilities in the areas of high-performance computing, artificial intelligence, and cybersecurity, as well as remote sensing applications.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.